Device specific vigilance guidance: Inferior vena cava (IVC) filters

AI Summary

This guidance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) details the reporting requirements for manufacturers of Inferior Vena Cava (IVC) filters. Operating under the regulatory framework of Statutory Instrument 2024 No. 1368, the document complements existing post-market surveillance standards. As this is a general guidance document rather than an enforcement action, specific company names and inspection dates are not applicable. The core focus is on categorizing and reporting device performance issues and clinical complications. Serious incidents, such as pulmonary embolisms, vascular perforations, mechanical failures of the implant, and severe allergic reactions, must be reported individually within statutory timescales. Other issues, including retrieval failures or minor wall erosion, may be eligible for Periodic Summary Reports (PSR) upon approval. Furthermore, manufacturers are required to perform trend reporting if there is a significant increase in the frequency or severity of issues like device migration, thrombosis, or improper placement. Manufacturers must use standardized IMDRF annex codes for all reports. The guidance emphasizes that multi-category incidents should be reported across all relevant formats to ensure comprehensive safety monitoring and regulatory compliance.